4ANQ

Structure of G1269A Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.76 Å
  • R-Value Free: 0.217 
  • R-Value Work: 0.201 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history. 


Literature

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Huang, Q., Johnson, T.W., Bailey, S., Brooun, A., Bunker, K.D., Burke, B.J., Collins, M.R., Cook, A.S., Cui, J.J., Dack, K.N., Deal, J.G., Deng, Y., Dinh, D., Engstrom, L.D., He, M., Hoffman, J., Hoffman, R.L., Johnson, P.S., Kania, R.S., Lam, H., Lam, J.L., Le, P.T., Li, Q., Lingardo, L., Liu, W., Lu, M.W., Mctigue, M., Palmer, C.L., Richardson, P.F., Sach, N.W., Shen, H., Smeal, T., Smith, G.L., Stewart, A.E., Timofeevski, S., Tsaparikos, K., Wang, H., Zhu, H., Zhu, J., Zou, H.Y., Edwards, M.P.

(2014) J Med Chem 57: 1170

  • DOI: 10.1021/jm401805h
  • Primary Citation of Related Structures:  
    4ANQ, 4ANL, 4CD0, 4CCB, 4CCU, 2YFX, 2YHV

  • PubMed Abstract: 

    • Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations ...

    Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

    Organizational Affiliation: 

    La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
ALK TYROSINE KINASE RECEPTORA342Homo sapiensMutation(s): 1 
Gene Names: ALK
EC: 2.7.10.1
Find proteins for Q9UM73 (Homo sapiens)
Explore Q9UM73 
Go to UniProtKB:  Q9UM73
NIH Common Fund Data Resources
PHAROS  Q9UM73
GTEx  ENSG00000171094
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
VGH
Query on VGH
Download Ideal Coordinates CCD File 
A
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
C21 H22 Cl2 F N5 O
KTEIFNKAUNYNJU-GFCCVEGCSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
VGHIC50:  11   nM  BindingDB
VGHIC50:  3039   nM  BindingDB
VGHIC50:  5.5   nM  BindingDB
VGHKi:  8.199999809265137   nM  BindingDB
VGHIC50:  1600   nM  BindingDB
VGHEC50:  22840   nM  BindingDB
VGHIC50:  1148   nM  BindingDB
VGHIC50:  5   nM  BindingDB
VGHIC50:  1.2000000476837158   nM  BindingDB
VGHIC50:  972   nM  BindingDB
VGHIC50:  1026   nM  BindingDB
VGHIC50:  17.600000381469727   nM  BindingDB
VGHIC50:  843   nM  BindingDB
VGHIC50:  2.0999999046325684   nM  BindingDB
VGHIC50:  600   nM  BindingDB
VGHIC50:  605   nM  BindingDB
VGHIC50:  626   nM  BindingDB
VGHIC50:  1   nM  BindingDB
VGHIC50:  478   nM  BindingDB
VGHIC50:  353   nM  BindingDB
VGHIC50:  355   nM  BindingDB
VGHIC50:  337   nM  BindingDB
VGHKd:  3.299999952316284   nM  BindingDB
VGHIC50:  220   nM  BindingDB
VGHIC50:  17.299999237060547   nM  BindingDB
VGHIC50:  188   nM  BindingDB
VGHIC50:  200   nM  BindingDB
VGHIC50:  148   nM  BindingDB
VGHIC50:  151   nM  BindingDB
VGHIC50:  165   nM  BindingDB
VGHIC50:  2.700000047683716   nM  BindingDB
VGHIC50:  605   nM  Binding MOAD
VGHIC50:  133   nM  BindingDB
VGHIC50:  110   nM  BindingDB
VGHIC50:  2   nM  BindingDB
VGHKd:  3.5999999046325684   nM  BindingDB
VGHIC50:  72   nM  BindingDB
VGHIC50:  78   nM  BindingDB
VGHIC50:  80   nM  BindingDB
VGHIC50:  51   nM  BindingDB
VGHEC50:  2042   nM  BindingDB
VGHIC50:  55   nM  BindingDB
VGHIC50:  56   nM  BindingDB
VGHIC50:  7.400000095367432   nM  BindingDB
VGHIC50:  36   nM  BindingDB
VGHIC50:  7.670000076293945   nM  BindingDB
VGHIC50:  0.6399999856948853   nM  BindingDB
VGHKi:  0.7400000095367432   nM  BindingDB
VGHIC50:  32   nM  BindingDB
VGHIC50:  28   nM  BindingDB
VGHIC50:  2.9000000953674316   nM  BindingDB
VGHIC50:  24   nM  BindingDB
VGHIC50:  25   nM  BindingDB
VGHIC50:  20   nM  BindingDB
VGHIC50 :  605   nM  PDBBind
VGHKd:  4.400000095367432   nM  BindingDB
VGHIC50:  14   nM  BindingDB
VGHEC50:  575   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.76 Å
  • R-Value Free: 0.217 
  • R-Value Work: 0.201 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.626α = 90
b = 57.473β = 90
c = 104.617γ = 90
Software Package:
Software NamePurpose
CNXrefinement
AutoPROCdata reduction
SCALAdata scaling
CNXphasing

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-03-27
    Type: Initial release
  • Version 1.1: 2014-03-19
    Changes: Atomic model, Database references
  • Version 1.2: 2019-05-08
    Changes: Data collection, Experimental preparation, Other